The myopathy of statins

被引：9

作者：

Smogorzewski, M ^{[1
]}

机构：

[1] Univ So Calif, Los Angeles Cty Med Ctr, Keck Sch Med, Dept Med,Div Nephrol, Los Angeles, CA 90033 USA

来源：

JOURNAL OF RENAL NUTRITION | 2005年 / 15卷 / 01期

关键词：

D O I：

10.1053/j.jrn.2004.09.033

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 ;

摘要：

Statins are first-line drugs for prevention and treatment of hypercholesterolemia and atherosclerotic disease. Despite the fact that statins are generally well tolerated and have a positive impact on human health, their myotoxic properties should keep physicians on alert. Mechanisms of statin-induced myopathy are still not fully understood. Phenotypic characteristics of patients, individual statin properties, and metabolic interaction with other drugs are important factors that may increase risk for statin myopathy. The lowest effective dose of statin should be used during treatment. Early recognition of myopathy and discontinuation of statin is critical in preventing serious sequelae such as rhabdomyolysis with all its complications. (C) 2005 by the National Kidney Foundation, Inc.

引用

收藏

页码：87 / 93

页数：7

相关论文

共 33 条

[1] Risk for myopathy with statin therapy in high-risk patients [J].

Ballantyne, CM ;

Corsini, A ;

Davidson, MH ;

Holdaas, H ;

Jacobson, TA ;

Leitersdorf, E ;

März, W ;

Reckless, JPD ;

Stein, EA .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564

[2] Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio [J].

DePinieux, G ;

Chariot, P ;

AmmiSaid, M ;

Louarn, F ;

Lejonc, JL ;

Astier, A ;

Jacotot, B ;

Gherardi, R .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) :333-337

[3] Effects of HMG-CoA reductase inhibitors on skeletal muscle - Are all statins the same? [J].

Evans, M ;

Rees, A .

DRUG SAFETY, 2002, 25 (09) :649-663

[4] BINDING OF DRUGS TO HUMAN MUSCLE [J].

FICHTL, B ;

KURZ, H .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 14 (05) :335-340

[5]

Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25

[6] Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].

Grundy, SM ;

Cleeman, JI ;

Merz, CNB ;

Brewer, HB ;

Clark, LT ;

Hunninghake, DB ;

Pasternak, RC ;

Smith, SC ;

Stone, NJ .

CIRCULATION, 2004, 110 (02) :227-239

[7] 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture [J].

Guijarro, C ;

Blanco-Colio, LM ;

Ortego, M ;

Alonso, C ;

Ortiz, A ;

Plaza, JJ ;

Diaz, C ;

Hernandez, G ;

Egido, J .

CIRCULATION RESEARCH, 1998, 83 (05) :490-500

[8] Ubiquinone: cholesterol's reclusive cousin [J].

Hargreaves, LP .

ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 :207-218

[9] Structural mechanism for statin inhibition of HMG-CoA reductase [J].

Istvan, ES ;

Deisenhofer, J .

SCIENCE, 2001, 292 (5519) :1160-1164

[10] Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors [J].

Kubota, T ;

Fujisaki, K ;

Itoh, Y ;

Yano, T ;

Sendo, T ;

Oishi, R .

BIOCHEMICAL PHARMACOLOGY, 2004, 67 (12) :2175-2186

← 1 2 3 4 →